Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Safety results from Phase 3b STRONG trial of durvalumab in patients with urinary tract carcinoma

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the primary results from the Phase IIIb STRONG trial (NCT03084471), which primarily investigated the safety of fixed-dose durvalumab monotherapy in patients with urinary tract carcinoma. Durvalumab was granted accelerated FDA approval in 2017 for use in this setting but due to the Phase III DANUBE trial failing to meet its primary endpoints in 2020, durvalumab has since been withdrawn from the market. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.